Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy

Abstract Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic purposes. We here evaluate clinical outcomes according to ER levels in a monoinstitutional cohort of non-metastatic triple-negative breast can...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Vittoria Dieci, Gaia Griguolo, Michele Bottosso, Vassilena Tsvetkova, Carlo Alberto Giorgi, Grazia Vernaci, Silvia Michieletto, Silvia Angelini, Alberto Marchet, Giulia Tasca, Elisa Genovesi, Enrico Cumerlato, Marcello Lo Mele, PierFranco Conte, Valentina Guarneri
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a5d10581508547cdb6d83e4a415f9496
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5d10581508547cdb6d83e4a415f9496
record_format	dspace
spelling	oai:doaj.org-article:a5d10581508547cdb6d83e4a415f94962021-12-02T17:06:26ZImpact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy10.1038/s41523-021-00308-72374-4677https://doaj.org/article/a5d10581508547cdb6d83e4a415f94962021-08-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00308-7https://doaj.org/toc/2374-4677Abstract Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic purposes. We here evaluate clinical outcomes according to ER levels in a monoinstitutional cohort of non-metastatic triple-negative breast cancer (BC) patients undergoing (neo)adjuvant chemotherapy. Clinicopathological data of 406 patients with ER < 10% HER2-negative BC treated with (neo)adjuvant chemotherapy between 01/2000 and 04/2019 were collected. Patients were categorized in ER-negative (ER < 1%; N = 364) and ER-low positive (1–9%, N = 42). At a median follow-up of 54 months, 88 patients had relapsed and 64 died. No significant difference was observed in invasive relapse-free survival (iRFS) and overall survival (OS) according to ER expression levels, both at univariate and multivariate analysis (5-years iRFS 74.0% versus 73.1% for ER-negative and ER-low positive BC, respectively, p = 0.6; 5-years OS 82.3% versus 76.7% for ER-negative and ER-low positive BC, respectively, p = 0.8). Among the 165 patients that received neoadjuvant chemotherapy, pathological complete response rate was similar in the two cohorts (38% in ER-negative, 44% in ER-low positive, p = 0.498). In conclusion, primary BC with ER1–9% shows similar clinical behavior to ER 1% BC. Our results suggest the use of a 10% cut-off, rather than <1%, to define triple-negative BC.Maria Vittoria DieciGaia GriguoloMichele BottossoVassilena TsvetkovaCarlo Alberto GiorgiGrazia VernaciSilvia MichielettoSilvia AngeliniAlberto MarchetGiulia TascaElisa GenovesiEnrico CumerlatoMarcello Lo MelePierFranco ConteValentina GuarneriNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maria Vittoria Dieci Gaia Griguolo Michele Bottosso Vassilena Tsvetkova Carlo Alberto Giorgi Grazia Vernaci Silvia Michieletto Silvia Angelini Alberto Marchet Giulia Tasca Elisa Genovesi Enrico Cumerlato Marcello Lo Mele PierFranco Conte Valentina Guarneri Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
description	Abstract Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic purposes. We here evaluate clinical outcomes according to ER levels in a monoinstitutional cohort of non-metastatic triple-negative breast cancer (BC) patients undergoing (neo)adjuvant chemotherapy. Clinicopathological data of 406 patients with ER < 10% HER2-negative BC treated with (neo)adjuvant chemotherapy between 01/2000 and 04/2019 were collected. Patients were categorized in ER-negative (ER < 1%; N = 364) and ER-low positive (1–9%, N = 42). At a median follow-up of 54 months, 88 patients had relapsed and 64 died. No significant difference was observed in invasive relapse-free survival (iRFS) and overall survival (OS) according to ER expression levels, both at univariate and multivariate analysis (5-years iRFS 74.0% versus 73.1% for ER-negative and ER-low positive BC, respectively, p = 0.6; 5-years OS 82.3% versus 76.7% for ER-negative and ER-low positive BC, respectively, p = 0.8). Among the 165 patients that received neoadjuvant chemotherapy, pathological complete response rate was similar in the two cohorts (38% in ER-negative, 44% in ER-low positive, p = 0.498). In conclusion, primary BC with ER1–9% shows similar clinical behavior to ER 1% BC. Our results suggest the use of a 10% cut-off, rather than <1%, to define triple-negative BC.
format	article
author	Maria Vittoria Dieci Gaia Griguolo Michele Bottosso Vassilena Tsvetkova Carlo Alberto Giorgi Grazia Vernaci Silvia Michieletto Silvia Angelini Alberto Marchet Giulia Tasca Elisa Genovesi Enrico Cumerlato Marcello Lo Mele PierFranco Conte Valentina Guarneri
author_facet	Maria Vittoria Dieci Gaia Griguolo Michele Bottosso Vassilena Tsvetkova Carlo Alberto Giorgi Grazia Vernaci Silvia Michieletto Silvia Angelini Alberto Marchet Giulia Tasca Elisa Genovesi Enrico Cumerlato Marcello Lo Mele PierFranco Conte Valentina Guarneri
author_sort	Maria Vittoria Dieci
title	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
title_short	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
title_full	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
title_fullStr	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
title_full_unstemmed	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
title_sort	impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a5d10581508547cdb6d83e4a415f9496
work_keys_str_mv	AT mariavittoriadieci impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT gaiagriguolo impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT michelebottosso impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT vassilenatsvetkova impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT carloalbertogiorgi impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT graziavernaci impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT silviamichieletto impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT silviaangelini impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT albertomarchet impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT giuliatasca impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT elisagenovesi impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT enricocumerlato impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT marcellolomele impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT pierfrancoconte impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy AT valentinaguarneri impactofestrogenreceptorlevelsonoutcomeinnonmetastatictriplenegativebreastcancerpatientstreatedwithneoadjuvantadjuvantchemotherapy
_version_	1718381630041620480

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy

Ejemplares similares